cutoff time point based on PK? [NCA / SHAM]

posted by Biostats – India, 2017-11-26 07:36 (1028 d 05:02 ago) – Posting: # 18006
Views: 2,060

Dear Sir,

Thanks for your prompt response

As per Methylphenidate FDA draft guidance cut-off time point should be Average of Tmax + 2*SD (Average and SD should be calculated from IR portion).

Can we apply this method for EMA submission?

Can we apply reference-scaling for all seven pk parameters or only for pk parameters from first phase i.e. Cmax(1) & AUC(1) as expected large intra-subject variability in first phase?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

Activity
 Admin contact
21,068 posts in 4,392 threads, 1,465 registered users;
online 8 (0 registered, 8 guests [including 5 identified bots]).
Forum time: Saturday 13:39 CEST (Europe/Vienna)

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5